Section Arrow
Quote
UTHR.NASDAQ
- United Therapeutics Corp
Quotes are at least 15-min delayed:2026/09/24 13:15 EDT
Regular Hours
Last
 473.575
-15.845 (-3.24%)
Day High 
481.3175 
Prev. Close
489.42 
1-M High
531.76 
Volume 
256.79K 
Bid
472.9
Ask
473.99
Day Low
469.2031 
Open
472.72 
1-M Low
477.01 
Market Cap 
20.99B 
Currency 美元 
P/E 17.54 
%Yield -- 
10-SMA 497.45 
20-SMA 501.62 
50-SMA 514.08 
52-W High 609.35 
52-W Low 409.07 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
27.91/30.61
Enterprise Value
21.29B
Balance Sheet
Book Value Per Share
149.22
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
3.18B
Operating Revenue Per Share
51.39
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
APUSApimeds Pharmaceuticals US Inc.5.855+3.565+155.68%-- 
HLNHaleon plc9.225+0.115+1.26%19PE
HIMSHims & Hers Health28.72+0.33+1.16%-- 
PRGOPerrigo Company PLC14.97+1.13+8.16%-- 
ELANElanco Animal Health22.185-0.385-1.71%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United Statesand Rest of the World, of which United States generates majority of the revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.